PDCD1 and neoplasm: The tumor mutational burden (TMB) is also previously reported to be correlated with anti-PD-1 therapy in multiple cancers, including urothelial carcinoma (Bellmunt et al., 2017) and metastatic NSCLC (Hellmann et al., 2019).